gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Irinotecan/Capecitabine versus Cisplatin/Capecitabine in Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction: Preliminary Results of a Randomized German AIO Phase II-Study

Meeting Abstract

  • corresponding author presenting/speaker Markus Möhler - Universitätsklinikum, Mainz, Deutschland
  • M. Geissler - Universitätsklinikum, Freiburg
  • H. Kanzler - Universitätsklinikum, Mainz
  • J. Raedle - Universitätsklinikum, Homburg
  • P. Malfertheiner - Universitätsklinikum, Magdeburg
  • W. Fischbach - Klinikum Aschaffenburg , Aschaffenburg
  • H. Scheruebl - Campus Benjamin Franklin, Berlin
  • T. Seufferlein - Universitätsklinikum, Ulm
  • P.R. Galle - Universitätsklinikum, Mainz
  • T. Hoehler - Universitätsklinikum, Mainz

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPE235

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Möhler et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Introduction: Irinotecan in combination with 5-FU is highly effective in advanced or metastatic gastric cancer. In addition, the oral administered fluoropyrimidine capecitabine seems to be at least as effective as 5-FU. Therefore, we designed this trail to prospectively compare efficacy and toxicity of the combination of irinotecan/capecitabine versus cisplatin/capecitabine.

Methods: Patients (pts) with previously untreated locally advanced or metastatic gastric or gastroesophageal adenocarcinoma were eligible with a Karnofsky Performance status (KPS) of at least 60%, measurable lesions and adequate major organ functions. Pts were randomized to receive 3-weekly cycles of either irinotecan 250 mg/m2, day 1 (arm A) or cisplatin 80 mg/m2, day 1 (arm B). Capecitabine was administered at 1000 mg/m2 twice daily for 14 days followed by a 7-day rest period in both treatment arms. Treatment was continued until progression of disease occurred.

Results: Preliminary results from an interim analysis will be present.